GDANSK (Reuters) - Switzerland's Galderma on Thursday said net sales rose 10.8% on a constant currency basis in the first half of 2024, driven by volume growth in all product categories, prompting the skin care company to give an upbeat outlook on its prospects.

Net sales were $2.2 billion in the six months through June, and Core EBITDA (earnings before interest, tax, depreciation and amortisation) reached $514 million, said the firm, which began trading on the stock exchange in March.

The company used the results to update its 2024 net sales guidance, and now expects annual sales to rise towards the upper end of its 7-10% range, measured on a constant currency basis.